Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
ValiRx intends to accelerate VAL101’s late pre-clinical studies in preparation for the compound’s
entry into the clinic. The company is working in partnership with commercial and academic
collaborators Deutsche Krebsforschungzentrum, the Institute of Oncology in Heidelberg and
Pharmatest Services Limited in Finland to progress the pre-clinical studies, and adding further
commercial partners in the US and China, in order to support manufacturing and clinical
development.
Conclusion
ValiRx is making good progress in the clinic with its two lead candidates. The signing of a value
enhancing deal with a development/commercial partner for VAL401 particularly, but also for VAL201,
looks not far off, as has been flagged by the company in recent RNSs. We believe that given the
current late stage of 401 in Phase III trials and the very real likelihood of a partnership deal on the
near horizon that the current post recent placing price of sub 2p provides an excellent opportunity to
enter into the stock in anticipation of such catalysts and that a re-rating to a realistic level is now
overdue. As has been evidenced before on positive trial RNSs, such news we believe would trigger
a large rise in the share price. Additionally, as well as cementing value within the development
portfolio, we would expect that any such partnership deal would include a funding element as well as
attract institutional investment, thus reducing the market’s concerns over this major risk to the
investment case and putting ValiRx into a higher league.
As discussed, our total probability of success weighted NPV for VAL201 and VAL401 is £54.64 million,
more than six times the current market cap. We use this to set our initial target price of 10.28p per
share. As ValiRx moves along the valuation curve we expect to reduce our discount rate and increase
the probability of success rate, thereby providing further upside potential. We point out that,
assuming successful approval for both drugs, the unrisked NPV (100% probability of success) rises to
£115.16 million, suggesting c.13 times upside. Accordingly, we initiate coverage of ValiRx with a
stance of Conviction Buy.
https://beta.companieshouse.gov.uk/officers/pRKnBKRa1UPSOQsnA0jG5Nbm2KY/appointments
British Managed Pharmaceuticals Company embarking on an aggressive planned growth in Bangladesh. British controlled and managed since August 2008. Company was taken over by the current management team headed by Atique Islam Choudhury in September 2015 on behalf of the founding European Investors.
Roses, so mean that MM would want to f*** themselves holding these shares in great numbers.
I would very much doubt that. MMs must want to unload these ASAP.
I must say I have 0 knowledge about and its just a wild guess.
https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-endocyte-expand-expertise-radiopharmaceuticals-and-build-commitment-transformational-therapeutic-platforms
Hope we could match this with 201